{"success":true,"data":{"pressRelease":{"id":"23716","rtpr_id":"nGNX9k72dm","ticker":"ALDX","exchange":"NASDAQ","all_tickers":["ALDX"],"title":"Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm","author":"Globe Newswire","published_at":"2026-05-06T16:00:00.211Z","article_body":"NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC,\na nationally recognized investor-rights law firm, announces that a class\naction lawsuit has been filed against Aldeyra Therapeutics, Inc. (NASDAQ:\nALDX) and certain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Aldeyra securities between\nNovember 3, 2023 and March 16, 2026, both dates inclusive (the “Class\nPeriod”). Such investors are encouraged to join this case by visiting the\nfirm’s site: bgandg.com/ALDX.\n(https://www.globenewswire.com/Tracker?data=s1vkjogfjgiG47aCtDbHYYx1vELuV1a0F2W_z7D1SPPgQUXedwhT7lEinQfG22GRIsuN19GNKgA7ic8AYKhVOdiIrao1O8OC2qzX3sobY17Pwyg-TaMOHd_6aHmajRywyUBE8DmEALLDp_ft_NjzPrBc2eoLSc2D7QZMr5Y0U24=)\n\nAldeyra Case Details\n\nThe Complaint alleges that Defendants throughout the Class Period made false\nand/or misleading statements and/or failed to disclose that:\n1. The results of the reproxalap (an Aldeyra drug candidate) clinical trials\nwere inconsistent;\n2. the inconsistency of the results rendered any purported positive findings\nfrom these trials unreliable and not meaningful; and\n3. as a result, defendants’ statements about Aldeyra’s business,\noperations, and prospects were materially false and misleading and/or lacked a\nreasonable basis at all relevant times.\nWhat's Next for Aldeyra Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm’s site: bgandg.com/ALDX.\n(https://www.globenewswire.com/Tracker?data=s1vkjogfjgiG47aCtDbHYYDyXxA1YXp9Bu_0W48WPcN_NUooew5QpgTACWrPkiIqcm9Zby5pocJkoZaNcv8jb2oc6iZMAyN3q3FkG8K9yyCwC4W9U3cfczEa_I7ncTiN4Vju-_zAq7joI6o15CBxGfTdiQKgdDYb0ErhLdEzIGM=)\nor you may contact Peretz Bronstein, Esq. or his Client Relations Manager,\nNathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you\nsuffered a loss in Aldeyra you have until May 29, 2026, to request that the\nCourt appoint you as lead plaintiff. Your ability to share in any recovery\ndoesn't require that you serve as lead plaintiff.\n\nNo Cost to Aldeyra Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys’ fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Aldeyra Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.globenewswire.com/Tracker?data=4Ppu5CRzmsyq9HWyfe99ptgMTSQMQsLx1HlGjp2aoiS8FrGFRRn8cwFdP_YByfYg0rB6D4k34QKGmN9sL8XyJz0vbZ20Os-ODU2cYCWWbrUHwe8ymI-l74Ksv6-9CB7IjxST0W2skFShK6pvyJMPtg==),\nFounding Partner of Bronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.globenewswire.com/Tracker?data=m0_Ujw9OKwSfufqmuH7Dz5jbvWra0D0oSv8ZadTrpFK2miwyNbW_z-MyAV-_R8vfDNxAp0JH1RHUFah7E0mgA6cnSHN10VyFIYWU2H6gG7KRgJsYNVzpb5PugF3dqyI1SS3Tuhx-GBrKOEYDgLKIxg==),\nX\n(https://www.globenewswire.com/Tracker?data=Ik4UFGztOsh044_jj_HL_Mzjj9DnCTDXpajiwenfvGPzyWtTljcXZFLLN6vpgBAudKr5sU-u9Cd3rQIaera_MA==),\nFacebook\n(https://www.globenewswire.com/Tracker?data=Eu0DwV6rJE5VYNbcDwy242xWQ7gffynTI-XjOtW2PEQuCzdkWizA-HR8RUo1D5ivAjTITKUVoClcCe53QnIp9HWGDHeb_Ms4sl4chHO0hqM=),\nor Instagram\n(https://www.globenewswire.com/Tracker?data=6snNOG1Vmm8BmkLjs49T-Kw0bovyEQMmtNbRJRZOAX5CMtn-lSwlZw7v7DQZ5uXBtNDw4CnK7YOMS2AUuXITBioqouF3WA0o1hTWqe4gaZo=).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1a031130-a9cc-48ff-b281-d1e47c9a91a5)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9k72dm","title":"Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm","author":"Globe Newswire","ticker":"ALDX","created":"2026-05-06T16:00:00.211Z","tickers":["ALDX"],"exchange":"NASDAQ","article_body":"NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC,\na nationally recognized investor-rights law firm, announces that a class\naction lawsuit has been filed against Aldeyra Therapeutics, Inc. (NASDAQ:\nALDX) and certain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Aldeyra securities between\nNovember 3, 2023 and March 16, 2026, both dates inclusive (the “Class\nPeriod”). Such investors are encouraged to join this case by visiting the\nfirm’s site: bgandg.com/ALDX.\n(https://www.globenewswire.com/Tracker?data=s1vkjogfjgiG47aCtDbHYYx1vELuV1a0F2W_z7D1SPPgQUXedwhT7lEinQfG22GRIsuN19GNKgA7ic8AYKhVOdiIrao1O8OC2qzX3sobY17Pwyg-TaMOHd_6aHmajRywyUBE8DmEALLDp_ft_NjzPrBc2eoLSc2D7QZMr5Y0U24=)\n\nAldeyra Case Details\n\nThe Complaint alleges that Defendants throughout the Class Period made false\nand/or misleading statements and/or failed to disclose that:\n1. The results of the reproxalap (an Aldeyra drug candidate) clinical trials\nwere inconsistent;\n2. the inconsistency of the results rendered any purported positive findings\nfrom these trials unreliable and not meaningful; and\n3. as a result, defendants’ statements about Aldeyra’s business,\noperations, and prospects were materially false and misleading and/or lacked a\nreasonable basis at all relevant times.\nWhat's Next for Aldeyra Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm’s site: bgandg.com/ALDX.\n(https://www.globenewswire.com/Tracker?data=s1vkjogfjgiG47aCtDbHYYDyXxA1YXp9Bu_0W48WPcN_NUooew5QpgTACWrPkiIqcm9Zby5pocJkoZaNcv8jb2oc6iZMAyN3q3FkG8K9yyCwC4W9U3cfczEa_I7ncTiN4Vju-_zAq7joI6o15CBxGfTdiQKgdDYb0ErhLdEzIGM=)\nor you may contact Peretz Bronstein, Esq. or his Client Relations Manager,\nNathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you\nsuffered a loss in Aldeyra you have until May 29, 2026, to request that the\nCourt appoint you as lead plaintiff. Your ability to share in any recovery\ndoesn't require that you serve as lead plaintiff.\n\nNo Cost to Aldeyra Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys’ fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Aldeyra Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.globenewswire.com/Tracker?data=4Ppu5CRzmsyq9HWyfe99ptgMTSQMQsLx1HlGjp2aoiS8FrGFRRn8cwFdP_YByfYg0rB6D4k34QKGmN9sL8XyJz0vbZ20Os-ODU2cYCWWbrUHwe8ymI-l74Ksv6-9CB7IjxST0W2skFShK6pvyJMPtg==),\nFounding Partner of Bronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.globenewswire.com/Tracker?data=m0_Ujw9OKwSfufqmuH7Dz5jbvWra0D0oSv8ZadTrpFK2miwyNbW_z-MyAV-_R8vfDNxAp0JH1RHUFah7E0mgA6cnSHN10VyFIYWU2H6gG7KRgJsYNVzpb5PugF3dqyI1SS3Tuhx-GBrKOEYDgLKIxg==),\nX\n(https://www.globenewswire.com/Tracker?data=Ik4UFGztOsh044_jj_HL_Mzjj9DnCTDXpajiwenfvGPzyWtTljcXZFLLN6vpgBAudKr5sU-u9Cd3rQIaera_MA==),\nFacebook\n(https://www.globenewswire.com/Tracker?data=Eu0DwV6rJE5VYNbcDwy242xWQ7gffynTI-XjOtW2PEQuCzdkWizA-HR8RUo1D5ivAjTITKUVoClcCe53QnIp9HWGDHeb_Ms4sl4chHO0hqM=),\nor Instagram\n(https://www.globenewswire.com/Tracker?data=6snNOG1Vmm8BmkLjs49T-Kw0bovyEQMmtNbRJRZOAX5CMtn-lSwlZw7v7DQZ5uXBtNDw4CnK7YOMS2AUuXITBioqouF3WA0o1hTWqe4gaZo=).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1a031130-a9cc-48ff-b281-d1e47c9a91a5)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-06T16:00:00.262589228Z","server_sent_at_ms":1778083200262},"received_at":"2026-05-06T16:00:00.373Z","source_url":null},"analysis":{"id":"18288","press_release_id":"23716","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman, LLC announced a class action lawsuit against Aldeyra Therapeutics, alleging violations of federal securities laws related to statements about its reproxalap drug candidate.\n\nThe lawsuit covers purchases made between November 3, 2023, and March 16, 2026, and the firm is soliciting investors to serve as lead plaintiff by a May 29, 2026 deadline.\n\nThis release is a plaintiff law-firm solicitation and does not constitute a new disclosure from the company; it is treated as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":["reproxalap"],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bronstein, Gewirtz & Grossman, LLC. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"ALDX"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bronstein, Gewirtz & Grossman, LLC announced a class action lawsuit against Aldeyra Therapeutics, alleging violations of federal securities laws related to statements about its reproxalap drug candidate.\n\nThe lawsuit covers purchases made between November 3, 2023, and March 16, 2026, and the firm is soliciting investors to serve as lead plaintiff by a May 29, 2026 deadline.\n\nThis release is a plaintiff law-firm solicitation and does not constitute a new disclosure from the company; it is treated as low-signal noise.","key_figures":{},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":["reproxalap"],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:1a3f9f8af9328a99","schema_hash":"sha256:dc6ca59cd3b6e100","created_at":"2026-05-07T02:18:32.758Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":null,"modelName":"glm-4.7"}}